What Is PT-141?
PT-141 (Bremelanotide) is classified as a melanocortin agonist peptide. Central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
It is extensively evaluated in laboratory and clinical settings for its potential to drive sexual arousal, libido. Researchers target PT-141 for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Nausea/hypertension possible. FDA-approved (Vyleesi) for HSDD in premenopausal women. Limited to 8 doses/month.
How Does PT-141 Work?
Central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
At the molecular level, PT-141 operates through pathways characteristic of the Melanocortin Agonist class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with sexual arousal, libido.
Expected Research Timeline
Weeks 2–4
Consistent improvement in sexual response and desire
Months 2–3
Psychological effects may plateau; effectiveness maintained with intermittent use
Long-Term
FDA-approved for long-term use; limit to 8 doses/month
What Does the Research Say?
The following are key findings from peer-reviewed studies on PT-141, indexed on PubMed and equivalent databases:
[1]PT-141 (Bremelanotide) for hypoactive sexual desire Phase 3
Kingsberg et al. (Obstet. & Gynecol.): Two identical Phase 3 RECONNECT trials showing bremelanotide significantly improves sexual desire and reduces distress in premenopausal women with HSDD.
Evidence: very strong[2]Bremelanotide Phase 3 efficacy and safety in HSDD
Clayton et al.: Phase 3 data confirming statistically significant improvements in desire metrics with favorable safety profile (nausea, flushing, headache). Led to FDA approval.
Evidence: very strong[3]PT-141 induces erection in men with erectile dysfunction
Diamond et al.: Double-blind, placebo-controlled study showing PT-141 induces significant erectile response at >7mg doses, effective even in PDE5 inhibitor non-responders.
Evidence: strong[4]Bremelanotide mechanism of action and pharmacology review
Comprehensive review of bremelanotide's MC4R mechanism, pharmacokinetics, clinical trial efficacy, and safety data across male and female sexual dysfunction studies.
Evidence: strongSafety & Side Effects
Nausea/hypertension possible. FDA-approved (Vyleesi) for HSDD in premenopausal women. Limited to 8 doses/month.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~40% of users | moderate |
| Flushing | ~20% of users | mild |
| Headache | ~10% of users | mild |
| Transient blood pressure increase | ~8% of users | moderate |
FDA Status: Approved
PT-141 has received FDA approval for specific clinical indications. Off-label uses remain under investigation.
How Is PT-141 Used?
Route
SubQ
Dose Range
1500–1500 mcg
Frequency
2x/wk
Cycle
Varies
Timing: 45 min before activity
Notes: FDA-approved dose: 1.75mg SubQ as needed. Max 1 dose per 24h, 8 doses/month.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
PT-141 vs. Related Compounds
| Compound | Primary Use |
|---|---|
| PT-141(this page) | Sexual arousal, libido |
| Melanotan II | Tanning, libido enhancement |
Where to Source PT-141 for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is PT-141?
PT-141 is a melanocortin agonist peptide. Central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
What are the primary research benefits of PT-141?
Published research identifies primary mechanisms targeting: Sexual arousal, libido. These findings come from 4+ peer-reviewed studies indexed in our database.
What is the half-life of PT-141?
In published pharmacokinetic data, PT-141 demonstrates a half-life of approximately 2.7 hours.
Is PT-141 FDA approved?
Yes, PT-141 has received FDA approval for specific indications. However, many research applications and off-label uses are still under investigation.
What are common side effects of PT-141?
Reported side effects in published literature include Nausea (~40% of users), Flushing (~20% of users), Headache (~10% of users), Transient blood pressure increase (~8% of users). Most are classified as moderate in severity.
How is PT-141 administered?
In research settings, PT-141 is typically administered via SubQ. FDA-approved dose: 1.75mg SubQ as needed. Max 1 dose per 24h, 8 doses/month.
Sources
- PT-141 (Bremelanotide) for hypoactive sexual desire Phase 3. View on PubMed
- Bremelanotide Phase 3 efficacy and safety in HSDD. View on PubMed
- PT-141 induces erection in men with erectile dysfunction. View on PubMed
- Bremelanotide mechanism of action and pharmacology review. View on PubMed